News
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
EQS-News: Abivax announces the resumption of its liquidity contract
EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Reports Business Update and Q3 2023 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and
EQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within
EQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
Poxel Announces its Participation at Upcoming Investor Conferences
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic